Early study reveals promising Alzheimer's disease treatment

July 18, 2008

A drug once approved as an antihistamine in Russia improved thinking processes and ability to function in patients with Alzheimer's disease in a study conducted there, said an expert at Baylor College of Medicine in Houston. The findings are published in the current issue of the journal The Lancet.

"More research is needed, but we are encouraged by the effect the drug Dimebon had on Alzheimer's patients" said Dr. Rachelle Doody, professor of neurology at BCM and lead author of the study.

In the study, the authors noted that Dimebon is the first drug for Alzheimer's disease that demonstrated continued improvement in patients over a 12 month period. Other approved drugs do not have this effect.

Half of the 183 patients in the Russian study received Dimebon; the other half were given a placebo or an inactive pill. Clinicians at the study sites then monitored the patients' progress over the next year on five different outcomes. All of those in the study had mild to moderate Alzheimer's disease.

"What we saw in the clinical trial is that people on the medication continued to improve over time," Doody said. "Those on placebo continued to decline."

Researchers believe the medication works by stabilizing mitochondria, the cellular components that produce energy, and possibly by inhibiting brain cell death. Researchers evaluated patients' thinking and memory ability, overall function, psychiatric and behavioral symptoms, and ability to perform daily activities.

"Usually at this point in a drug's development, we are happy to see improvement in one of the outcome measures," Doody said. "We saw improvement in all five."

Some participants complained of occasional dry mouth, but no one opted out of the study because of the side effects.

"As we continue research, we hope to replicate these results," Doody said. "My belief is that this drug will turn out to be useful for Alzheimer's disease, regardless of the stage of the disease."

Doody said this is only the first study looking into the effects of Dimebon on Alzheimer's disease. She also noted that it involved only a relatively small population from one specific region of the world. The ongoing Phase 3 study will include several international locations including the United States.

Source: Baylor College of Medicine

Explore further: Altering RNA helicases in roundworms doubles their lifespan

Related Stories

Altering RNA helicases in roundworms doubles their lifespan

July 21, 2015

The things we do to extend our lives—quitting smoking, cutting back on carbs, taking up jogging —all have some impact on our longevity, if only just a little. But no matter how hard we work towards chasing the dream ...

A tale of two roads into protein unfolding

May 11, 2015

You are taking a class on origami and Mr. Otaki asks you to fold that little red piece of paper into a very elaborate design. You have to do it in a very short time. You try your best but you fail. Your origami sucks!

High-tech sensors help kids keep eye on aging parents

May 5, 2015

Each time 81-year-old Bill Dworsky or his 80-year-old wife Dorothy opens the refrigerator, closes the bathroom door or lifts the lid on a pill container, tiny sensors in their San Francisco home make notes on a digital logbook.

New technology maps human genome in days

May 5, 2015

The two 3-by-1-inch glass chips held the unfathomable amount of genetic information contained in 16 human genomes. Last week, a technician placed the chips - called flow cells - in a new genetic sequencing machine at the ...

Recommended for you

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

(PhysOrg.com) -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...

Quantum Theory May Explain Wishful Thinking

April 14, 2009

(PhysOrg.com) -- Humans don’t always make the most rational decisions. As studies have shown, even when logic and reasoning point in one direction, sometimes we chose the opposite route, motivated by personal bias or simply ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.